Role of CYP3A in bromperidol metabolism in rat in vitro and in vivo

Xenobiotica

Volumn 29, Issue 8, 1999, Pages 839-846

  Watanabe, M ^a   Tateishi, T ^a   Tanaka, M ^a   Kumai, T ^a   Kobayashi, S ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMPERIDOL; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DIETHYLDITHIOCARBAMIC ACID; ERYTHROMYCIN; FURAFYLLINE; NEUROLEPTIC AGENT; QUININE; TROLEANDOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME INHIBITORS; ERYTHROMYCIN; HALF-LIFE; HALOPERIDOL; IMMUNE SERA; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PROPIONIC ACIDS; QUININE; RATS; RATS, SPRAGUE-DAWLEY; STEROID HYDROXYLASES; THEOPHYLLINE; TROLEANDOMYCIN;

EID: 0032863787     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238281     Document Type: Article

References (30)

1. AMEER, B. and WEINTRAUB, R. A., 1997, Drug interactions with grapefruit juice. Clinical Pharmaco-kinetics, 33, 103-121.
2. BENFIELD, P., WARD, A., CLARK, B. G. and JUE, S. G., 1988, Bromperidol. A preliminary review of its pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs, 35, 670-684.
3. BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 768-774.
4. BRANNEN, J. O., MCEVOY, J. P., WILSON, W. H., PETRIE, W. M., BAN, T, A., BERNEY, S. A. and SCHAFFER, J. D., 1981, A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatrie, 14, 139-140.
5. CHASSEAUD, L. F., 1978, Metabolic fate of bromperidol in human: comparison with rats and dogs. Acta Psychiatria Belgica, 78, 51-63.
6. DENJIS, E. L., 1980, Clinical evaluation of bromperidol versus haloperidol in psychotic patients. International Pharmacopsychiatry, 15, 309-317.
7. FANG, J., BAKER, G. B., SILVERSTONE, P. H. and COUTTS, R. T., 1997. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cellular and Molecular Neurobiology, 17, 227-233.
8. FANG, J. and GORROD, J. W., 1993, High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. Journal of Chromatography, 614, 267-273.
9. HEYKANTS, J., MEULDERMANS, W. and MICHIELS, M., 1978, Absorption, excretion and metabolism of oral bromperidol in rats and dog. European Journal of Drug Metabolism and Pharmacokinetics, 2, 111-117.
10. ITOH, H., 1985, A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique. Psychopharmacology Bulletin, 21, 120-122.
11. KERRY, N. L., SOMOGYI, A. A., MIKUS, G. and BOCHNER, F., 1993, Primary and secondary oxidative metabolism of dextromethorphan. Biochemical Pharmacology, 45, 833-839.
12. KOBAYASHI, S., MURRAY, S., WATSON, D., SESARDIC, D., DAVIES, D. S. and BOOBIS, A. R., 1989, The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochemical Pharmacology, 38, 2795-2799.
13. KOLARS, J. C., STETSON, P. L., RUSH, B. D., RUWART, M. J., SCHMIEDLIN-REN, P., DUELL, E. A., VOORHEES, J. J. and WATKINS, P. B., 1992, Cyclosporine metabolism by P450IIIA in rat enterocytes - Another determinant of oral bioavailability? Transplantation, 53, 596-602.
14. KUDO, S. and ODOMI, M., 1998, Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. European Journal of Clinical Pharmacology, 54, 253-259.
15. KUNZE, K. L. and TRAGER, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline, Chemical Research in Toxicology, 6, 649-656.
16. KÜPFER, A., SCHMID, B., PREISIG, R. and PFAFF, G., 1984, Dextromethorphan as a safe probe for debrisoquin hydroxylation polymorphism. Lancet, 2, 517-518.
17. LLERENA, A., ALM, C., DAHL, M. L., EKQVIST, B. and BERTILSSON, L., 1992, Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Therapeutic Drug Monitoring, 14, 92-97.
18. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin Phenol reagent. Journal of Biological Chemistry, 193, 265-275.
19. MALFROID, M., HENS, L., ROOSEN, P. and DOM, R., 1978, Double-blind evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients, Acta Psychiatrica Belgica, 78, 147-154.
20. MURRAY, B. M., EDWARDS, L., MORSE, G. D., KOHLI, R. R. and VENUTO, R. C., 1992, Clinically important interaction of cyclosporine and erythromycin. Transplantation, 43, 602-604.
21. NUNOYA, K., YOKOI, T., KIMURA, K., KODAMA, T., FUNAYAMA, M., INOUE, K., NAGASHIMA, K., FUNAE, Y., SHIMADA, N., GREEN, C. and KAMATAKI, T., 1996, ( + )-Cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 768-774.
22. OTANI, K., ISHIDA, M., YASUI, N., KONDO, T., MIHARA, K., SUZUKI, A., KANEKO, S., INOUE, Y., SHIBATA, M. and IKEDA, K., 1997, No effect of the anticholinergic drugs trihexyphenidyl and biperidine on the plasma concentrations of bromperidol and its reduced metabolite. Therapeutic Drug Monitoring, 19, 165-168.
23. PAN, L. P., WIJNANT, P., VRIENDT, C. D., ROSSEEL, M. T. and BELPAIRE, F. M., 1997, Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. British Journal of Clinical Pharmacology, 44, 557-564.
24. SCHENKMAN, J. B., WILSON, B. J. and CINTI, D. L., 1972, Diethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A) - in vivo and in vitro effects of metabolism by rat liver microsomes - formation of an oxygenated complex. Biochemical Pharmacology, 21, 2373-2383.
25. SOMEYA, T., INABA, T., TYNDALE, R. F., TANG, S. W. and TAKAHASHI, S., 1991, Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology, 5, 177-182.
26. SPINA, E., MARTINES, C., CAPUTI, A. P., COBALEDA, J., PINASE, B., CARRILLO, J. A. and BENITEZ, J., 1991, Debrisoquine oxidation phenotype during neuroleptic monotherapy. European Journal of Clinical Pharmacology, 41, 467-470.
27. SUZUKI, A., OTANI, K., ISHIDA, M., YASUI, N., KONDO, T., MIHARA, K., KANEKO, S., INOUE, Y., SHIBATA, M. and IKEDA, K., 1997, Increased plasma concentration of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Therapeutic Drug Monitoring, 19, 261-264.
28. THUMMEL, K. E. and WILKINSON, G. R., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology, 38, 389-430.
29. TYNDALE, R. F., KALOW, W. and INABA, T., 1991, Oxidation of reduced haloperidol to haloperidol: involvement of human P4501ID6 (spartein/debrisoquine monooxygenase). British Journal of Clinical Pharmacology, 31, 655-660.
30. WONG, F. A., BATEMAN, C. P., SHAW, C. J. and PATRICK, J. E., 1983, Biotransformation of bromperidol in rat, dog, and man, Drug Metabolism and Disposition, 11, 301-307.